Mogrify

Mogrify is an innovative life science company that focuses on transforming the lives of patients suffering from degenerative diseases through its unique in vivo reprogramming therapies. The company creates these therapies using its proprietary MOGRIFY® and epiMOGRIFY® platforms which leverage transcriptomic and epigenetic data to identify optimal combinations of transcription factors and growth factors required to convert a variety of cell types. Originated with a focus on applications in ophthalmology, otology, metabolic and other degenerative disease areas, Mogrify aims to generate the functional cell types required to address diseases with a high unmet clinical need.

Since its foundation, the company has made significant strides and milestones in its field. Starting the development of its revolutionary MOGRIFY® platform in 2011, Mogrify was officially incorporated in 2016 by three academic Co-founders: J. Gough, O. Rackham & J. Polo. The company has witnessed considerable growth and validation in which it raised $3.7M in seed capital, appointed Dr. Darrin M.Disley as CEO, and 40 scientists were hired. By 2020, Mogrify launched the epiMOGRIFY® cell identity platform and managed to raise a total of $33M in Series A in 2021, which aided in the advancement of the in vivo reprogramming programs toward Investigational New Drug (IND)-enabling studies.

Mogrify presents a promising interest for potential investors and partners in the field of regenerative medicine, in vivo reprogramming, and ex vivo cell therapy. The company continues to apply its revolutionary approach to creating therapies across a wide range of degenerative diseases, hence offering immense potential in advancing medical treatments. With plans to continue developing in vivo reprogramming therapy, Mogrify is a company one should consider for both its current achievements and potential future breakthroughs in life sciences.

Connect